Cassava Sciences
Stock
Stock
ISIN: US14817C1071
Ticker: SAVA
US14817C1071
SAVA
Price
Price
CHART BY
Frequently asked questions
What is Cassava Sciences's market capitalization?
The market capitalization of Cassava Sciences is $135.91M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Cassava Sciences?
Cassava Sciences's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.37. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Cassava Sciences's stock?
Currently, 3 analysts cover Cassava Sciences's stock, with a consensus target price of $59.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Cassava Sciences?
Cassava Sciences's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$140.42M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Cassava Sciences?
Cassava Sciences has a free cash flow of -$78.07M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Cassava Sciences have, and what sector and industry does it belong to?
Cassava Sciences employs approximately 29 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Cassava Sciences's shares?
The free float of Cassava Sciences is 41.80M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $135.91M
- EPS (TTM)
- -$1.37
- Free Float
- 41.80M
- EBITDA (TTM)
- -$140.42M
- Free Cashflow (TTM)
- -$78.07M
Pricing
- 1D span
- $2.698$2.911
- 52W span
- $2.24$42.19
Analyst Ratings
The price target is $59.00 and the stock is covered by 3 analysts.
Buy
0
Hold
2
Sell
1
Information
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
- Employees
- 29
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US14817C1071
- Primary Ticker
- SAVA